Botta L, Mira E, Valli S, Zucca G, Perin P, Benvenuti C, Fossati A, Valli P
Department of Physiological and Pharmacological Sciences, University of Pavia, Italy.
Acta Otolaryngol. 2000 Jan;120(1):25-7. doi: 10.1080/000164800760370783.
Previous studies have demonstrated that betahistine, an histamine-like substance used widely as an anti-vertigo drug, can decrease ampullar receptor resting discharge without affecting their mechanically evoked responses. Pharmacokinetic studies have shown that this drug is transformed, mainly at the hepatic level, into aminoethylpyridine (M1), hydroxyethylpyridine (M2), then excreted with the urine as pyridylacetic acid (M3). The goal of the present study was to investigate whether betahistine metabolites are also able to affect vestibular receptor activity. Results demonstrated that, in the range tested (10(-7)-10(-2) M), M2 and M3 exerted no effect, whereas M1, at concentrations higher than 10(-6) M, was able to reduce the resting discharge of ampullar receptors without affecting the evoked responses. M1 therefore exerts effects similar to those of betahistine on ampullar receptors. This might be of some clinical interest. On the basis of our data, the hypothesis may be put forward that the anti-vertigo action of betahistine is at first achieved by betahistine itself and then sustained by M1.
先前的研究表明,倍他司汀作为一种广泛使用的抗眩晕药物,是一种组胺样物质,它可以降低壶腹嵴受体的静息放电,而不影响其机械诱发反应。药代动力学研究表明,该药物主要在肝脏水平转化为氨基乙基吡啶(M1)、羟乙基吡啶(M2),然后以吡啶乙酸(M3)的形式随尿液排出。本研究的目的是调查倍他司汀的代谢产物是否也能够影响前庭受体的活性。结果表明,在所测试的浓度范围内(10^(-7)-10^(-2) M),M2和M3没有作用,而M1在浓度高于10^(-6) M时,能够降低壶腹嵴受体的静息放电,而不影响诱发反应。因此,M1对壶腹嵴受体的作用与倍他司汀相似。这可能具有一定的临床意义。根据我们的数据,可以提出这样的假设,即倍他司汀的抗眩晕作用首先由倍他司汀本身实现,然后由M1维持。